Format

Send to

Choose Destination
Pharmacotherapy. 2019 Sep 5. doi: 10.1002/phar.2326. [Epub ahead of print]

Parenteral Fosfomycin: A New Ally in the Fight Against Multidrug-Resistant Bacterial Pathogens.

Author information

1
Medication Outcomes Center, Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, San Francisco, CA.
2
Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University, High Point, NC.
3
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI.

Abstract

Fosfomycin was initially discovered in 1969 but has recently gained renewed interest for the treatment of multidrug-resistant (MDR) bacterial infections, particularly in the United States. Its unique mechanism of action, bactericidal activity, broad spectrum of activity, and relatively safe and tolerable adverse effect profile make it a great addition to the dwindling antibiotic armamentarium. Fosfomycin contains a three-membered epoxide ring with a direct carbon to phosphorous bond, which bypasses the intermediate oxygen bond commonly present in other organophosphorous compounds; this structure makes the agent unique from other antibiotics. Despite nearly five decades of parenteral fosfomycin use in Europe, fosfomycin has retained stable activity against most pathogens. Furthermore, fosfomycin demonstrated in vitro synergy in combination with other cell wall-active antibiotics (e.g., β-lactams, daptomycin). These combinations may offer respite for severe infections due to MDR gram-positive and gram-negative bacteria. The intravenous formulation is currently under review in the United States, and apropos, this review collates more contemporary evidence (i.e., studies published between 2000 and early 2019) in anticipation of this development. The approval of intravenous fosfomycin provides another option for consideration in the management of MDR infections. Its unique structure will give rise to a promising epoxide epoch in the battle against MDR bacteria. This article is protected by copyright. All rights reserved.

KEYWORDS:

MDR ; Contepo; ZTI-01; combination; fosfomycin disodium; in vitro synergy; phosphomycin; resistance; susceptibility

PMID:
31487056
DOI:
10.1002/phar.2326

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center